New data endorse microdosing in drug development

Maryland, USA-based Xceleron says that preliminary results from the European Union Microdose AMS Partnership Program (EUMAPP) further endorse the growing body of microdose data that predicts pharmacological dose ADME/PK outcomes.

The EUMAPP consortium presented preliminary results from the 30-month, 2.0 million-euro ($3.1 million) project at the European Federation for Pharmaceutical Sciences (EUFEPS) conference in Bad Homburg, Germany. The compounds selected for the EUMAPP were chosen to rigorously test the predictability of human microdosing by studying drugs that exhibited properties in humans that are difficult to predict in animal or in vitro models and drugs with properties that, it was suspected, might be difficult to predict at a therapeutic dosage from microdose data.

Of the 25 molecules now tested at both pharmacological and microdose, human microdosing is found to be over 80% predictive, said Xceleron.